A new microbicide built from two types of RNA has shown promise against HIV in lab experiments, but moving it toward becoming a marketable product is proving difficult. Alan Dove investigates what’s interfering with this novel therapeutic RNA strategy. (Click here to continue reading)

Illustration by Marina Corral